Sign up here to receive news updates via email.
-
August 17, 2016 |
Media, Press Releases
BERG Strengthens Financial Leadership And Expands Board Of Directors
read moreBOSTON, Aug. 17, 2016 /PRNewswire/ — BERG, a technology-based biopharmaceutical company uncovering health solutions through a data-driven, systems biological research approach, today announced an expansion of its Board of Directors, adding three new members who bring a wealth of healthcare, financial and executive leadership to the company. The additions to BERG’s Board of Directors include Shumeet…
-
June 5, 2016 |
Media, Press Releases
BERG Announces Clinical Trial Data Presentations Of BPM 31510 In Advanced Solid Tumors And BPM 31543 For Prevention Of Chemotherapy-Induced Alopecia At American Society of Clinical Oncology Annual Meeting
read moreBOSTON, June 5, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it will present two poster presentations on the Phase 1 study of BPM 31510 (IV) in advanced solid tumors and BPM 31543 for the prevention of chemotherapy-induced alopecia at the American Society of…
-
April 27, 2016 |
Media, Press Releases
BERG Initiates Phase II Combination Trial Of BPM 31510 And Gemcitabine In Patients With Pancreatic Cancer
read moreBOSTON, April 27, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced that it has initiated a Phase II clinical trial for its drug candidate BPM 31510 in combination with gemcitabine for the potential treatment of pancreatic cancer. The primary objective of the trial is to evaluate…
-
April 18, 2016 |
Media, Press Releases
BERG Announces BPM31510 Data Presentations At 2016 AACR Annual Meeting
read moreBOSTON, April 18, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced five poster presentations showing new promising preclinical pancreatic cancer data, including new biomarkers for detection and improved treatment outcomes via the combination of BPM31510 with gemcitabine. Additionally new data demonstrates molecular drivers of endothelial cell…
-
February 23, 2016 |
Media, Press Releases
BERG Appoints Michael A. Kiebish As Chief Precision Medicine Officer
read moreNew CPMO position spotlights growing importance of precision medicine in disease treatment Feb 23, 2016, 09:04 ET from BERG BOSTON, Feb. 23, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, today announced the appointment of Michael A. Kiebish, Ph.D. as Chief Precision Medical Officer. In the newly created role, Kiebish will…
-
February 9, 2016 |
Media, Press Releases
BERG Appoints Narain To Chief Executive Officer; Haddock Joins As Chief Financial Officer/ Chief Operating Officer
read moreBERG Hires Bristol-Myers Squibb Former Head of Finance Feb 09, 2016, 09:02 ET from BERG BOSTON, Feb. 9, 2016 /PRNewswire/ — BERG, a biopharmaceutical company uncovering health solutions through a data-driven, biological research approach, has announced the appointment of Jason Haddock as Chief Financial Officer and Chief Operating Officer. Haddock brings to BERG over 20 years of experience in corporate…
